 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
13 News |  |
| «123 |
- ||||| bersacapavir (JNJ-56136379) / J&J
New P2a trial, Combination therapy, Monotherapy: JADE: An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection (clinicaltrials.gov) - Dec 5, 2017
P2a, N=220, Not yet recruiting, Sponsor: Janssen Sciences Ireland UC
- | bersacapavir (JNJ-56136379) / J&J
Trial completion: A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4) (clinicaltrials.gov) - Sep 6, 2017
P1, N=18, Completed, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Completed
- | bersacapavir (JNJ-56136379) / J&J
New P1 trial: A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4) (clinicaltrials.gov) - Apr 12, 2017
P1, N=18, Recruiting, Sponsor: Janssen Sciences Ireland UC
- | bersacapavir (JNJ-56136379) / J&J
Trial completion, Enrollment change: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants (clinicaltrials.gov) - Mar 13, 2017
P1, N=39, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Recruiting --> Completed | N=32 --> 39
- || bersacapavir (JNJ-56136379) / J&J
Trial primary completion date: A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) (clinicaltrials.gov) - Jan 4, 2017
P1, N=84, Recruiting, Sponsor: Janssen Sciences Ireland UC
Recruiting --> Completed | N=32 --> 39 Trial primary completion date: Nov 2016 --> Nov 2017
- bersacapavir (JNJ-56136379) / J&J
Enrollment open: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants (clinicaltrials.gov) - Nov 14, 2016
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Nov 2016 --> Nov 2017 Not yet recruiting --> Recruiting
- | bersacapavir (JNJ-56136379) / J&J
New P1 trial: A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants (clinicaltrials.gov) - Oct 13, 2016
P1, N=32, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| bersacapavir (JNJ-56136379) / J&J
Enrollment open: A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) (clinicaltrials.gov) - Sep 28, 2016
P1, N=84, Recruiting, Sponsor: Janssen Sciences Ireland UC
Not yet recruiting --> Recruiting Suspended --> Recruiting
- | bersacapavir (JNJ-56136379) / J&J
Trial suspension: A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) (clinicaltrials.gov) - Sep 12, 2016
P1, N=78, Suspended, Sponsor: Janssen Sciences Ireland UC
Suspended --> Recruiting Recruiting --> Suspended
- ||| bersacapavir (JNJ-56136379) / J&J
New P1 trial: A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II) (clinicaltrials.gov) - Feb 11, 2016
P1, N=78, Recruiting, Sponsor: Janssen Sciences Ireland UC